Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus [Canadian Business Journal (Canada)]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Canadian Business Journal
VANCOUVER, British Columbia, March 06, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company The decision was made based on the results of an independent study of Ifenprodil which showed a 40% improvement in mortality and significantly reduced acute lung injury (ALI) in a recent H5N1 animal study. H5N1 is one of the most lethal form of influenza known with a 53% mortality rate. Since Ifenprodil is an already approved drug with a known safety history, it can be safely administered to patients without additional pre-clinical testing. “If we see a similar response in coronavirus patients as seen in the H5N1 animal study, a far more lethal form of influenza, we believe that patient outcomes should be significantly improved”, said Christopher J. Moreau, CEO of Algernon. Algernon welcomes contact from health organizations and physicians globally to learn more about NP-120 (Ifenprodil). Management’s belief that NP-120 (Ifenprodil) is
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi to overhaul US operations of vaccines, cut jobs [Reuters]Reuters
- Sanofi to overhaul US operations of vaccines, cut jobs [Yahoo! Finance]Yahoo! Finance
- Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1) [Yahoo! Finance]Yahoo! Finance
- Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)PR Web
- COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- 3/20/24 - Form 6-K
- SNY's page on the SEC website